CN102309516A - Drug composition and application thereof - Google Patents
Drug composition and application thereof Download PDFInfo
- Publication number
- CN102309516A CN102309516A CN 201110125426 CN201110125426A CN102309516A CN 102309516 A CN102309516 A CN 102309516A CN 201110125426 CN201110125426 CN 201110125426 CN 201110125426 A CN201110125426 A CN 201110125426A CN 102309516 A CN102309516 A CN 102309516A
- Authority
- CN
- China
- Prior art keywords
- inorganic acid
- acid salt
- pharmaceutical composition
- pharmaceutical
- tetravalence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Catalysts (AREA)
Abstract
The invention relates to a drug composition, belonging to the field of chemical drugs. The drug composition comprises the following active ingredient: inorganic acid salt of tetravalent V. The clinical research indicates that after being used, the drug does not have obvious toxic or side effect, has an obvious effect and takes an effect quickly. The invention provides a new option for treating diseases such as syphilis, psoriasis, alopecia, angiitis and the like, and the drug composition has broad market prospect.
Description
Technical field
The present invention relates to a kind of medical composition and its use, belong to the chemical medicine field.
Background technology
Vanadium is one of trace element necessary in the human body, and vanadium is extremely low at the intravital content of people, and insufficient total amount is 1 milligram in the body, mainly is distributed in internal organs, positions such as liver, kidney, thyroid especially, and content is also higher in the osseous tissue.Vanadium is merely 5% at the gastrointestinal absorbance, and its absorption site is mainly at upper digestive tract.About 95% vanadium combines with transferrins with ionic condition and carries in the blood, so vanadium and ferrum can interact in human body.Vanadium is a many-side in the intravital function of people, and the most approved vanadium lacks the research to goat and white mouse that performance comes from report in 1987, and the goat that vanadium lacks shows the abortion ratio increase and milk yield reduces.In the white mouse experiment, the vanadium shortage causes growth inhibited, and the reproduction function is weak, the ratio increase of thyroid weight and body weight and the variation of plasma thyroid hormones concentration.At present, still indeterminate for the research of human body vanadium deficiency disease.
Summary of the invention
First technical problem to be solved by this invention provides a kind of pharmaceutical composition.
Pharmaceutical composition of the present invention comprises the inorganic acid salt of following active component: tetravalence V.
Further, better for the drug effect that makes medicine, the active component of aforementioned pharmaceutical compositions also comprises the inorganic acid salt of pentavalent V.Wherein, the content of vanadium of the inorganic acid salt of pentavalent V be preferably tetravalence V the inorganic acid salt content of vanadium 0.5%～5%.
Further, better for the drug effect that makes medicine, the active component of aforementioned pharmaceutical compositions also comprises proper inorganic acid, and wherein, said mineral acid can be hydrochloric acid, sulphuric acid or phosphoric acid.When active ingredient in pharmaceutical contained mineral acid, it was preferably solution dosage, and the consumption of mineral acid gets final product to guarantee that active component dissolves fully.
Further, better for the drug effect that makes medicine, the active component of aforementioned pharmaceutical compositions also comprises the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge.Wherein, the inorganic acid salt content of K, Na, Fe, Al, Ti, Se, Li, Ge preferably be respectively V the inorganic acid salt integral molar quantity 10
-6～10
-5Doubly; The inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is preferably chlorate, sulfate or phosphate.
The active component of aforementioned pharmaceutical compositions can be merely the inorganic acid salt of tetravalence V.
Wherein, the active component of aforementioned pharmaceutical compositions can also be inorganic acid salt and the proper inorganic acid of tetravalence V; Described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid.When active ingredient in pharmaceutical contained mineral acid, it was preferably solution dosage, and the consumption of mineral acid gets final product to guarantee that active component dissolves fully.
Wherein, the active component of aforementioned pharmaceutical compositions can also be the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge and the inorganic acid salt of tetravalence V; The inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate.The inorganic acid salt content of described K, Na, Fe, Al, Ti, Se, Li, Ge preferably be respectively tetravalence V the inorganic acid salt mole 10
-6～10
-5Doubly.
Wherein, the active component of aforementioned pharmaceutical compositions can also be the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge, the inorganic acid salt of tetravalence V and proper inorganic acid; Described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid; The inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate.The inorganic acid salt content of described K, Na, Fe, Al, Ti, Se, Li, Ge preferably be respectively tetravalence V the inorganic acid salt mole 10
-6～10
-5Doubly.
Wherein, the active component of aforementioned pharmaceutical compositions also can be the inorganic acid salt of tetravalence V and the inorganic acid salt of pentavalent V.The content of vanadium of the inorganic acid salt of described pentavalent V be preferably tetravalence V the inorganic acid salt content of vanadium 0.5%～5%.
Wherein, said active ingredient in pharmaceutical can also be the inorganic acid salt of tetravalence V, inorganic acid salt and the proper inorganic acid of pentavalent V; Described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid.The content of vanadium of the inorganic acid salt of described pentavalent V be preferably tetravalence V the inorganic acid salt content of vanadium 0.5%～5%.
Wherein, said active ingredient in pharmaceutical can also be the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge, the inorganic acid salt of the inorganic acid salt of tetravalence V and pentavalent V; The inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate.The content of vanadium of the inorganic acid salt of described pentavalent V be preferably tetravalence V the inorganic acid salt content of vanadium 0.5%～5%.Further, the inorganic acid salt content of described K, Na, Fe, Al, Ti, Se, Li, Ge preferably be respectively V the inorganic acid salt integral molar quantity 10
-6～10
-5Doubly.
Wherein, said active ingredient in pharmaceutical can also be the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge, the inorganic acid salt of tetravalence V, the inorganic acid salt of pentavalent V and proper inorganic acid; Described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid; The inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate.The content of vanadium of the inorganic acid salt of described pentavalent V be preferably tetravalence V the inorganic acid salt content of vanadium 0.5%～5%.Further, the inorganic acid salt content of described K, Na, Fe, Al, Ti, Se, Li, Ge preferably be respectively V the inorganic acid salt integral molar quantity 10
-6～10
-5Doubly.
Wherein, the inorganic acid salt of the V in the aforementioned pharmaceutical compositions is preferably sulfate, chlorate or phosphate.Further, when V was tetravalence, the inorganic acid salt of V was preferably: VCl
4, VOCl
2, VOSO
4, (VO)
3(PO
4)
2, VOHPO
4Or VO (H
2PO
4)
2When V was pentavalent, the inorganic acid salt of V was preferably VOCl
3, (VO
2)
2(SO
4)
3, VOPO
4, (VO)
2(HPO
4)
3Or VO (H
2PO
4)
3
Inventor of the present invention is through discovering that the vanadium cation that contains in the pharmaceutical composition of the present invention is a main active.Therefore, the present invention also provides a kind of pharmaceutical composition, and it comprises following active component: VO
2+
Further, the active component of aforementioned pharmaceutical compositions also comprises VO
2 +Wherein, VO
2 +Content is preferably VO
2+0.5%～5% of mole.
Further, the active component of aforementioned pharmaceutical compositions also comprises K
+, Na
+, Fe
2+, Al
3+, Ti
4+, Se
4+, Li
+And/or Ge
4+Wherein, K
+, Na
+, Fe
2+, Al
3+, Ti
4+, Se
4+, Li
+, Ge
4+Content preferably be respectively V integral molar quantity 10
-6～10
-5Doubly.
Further, active ingredient in pharmaceutical of the present invention also can be VO
2+Or
Said active ingredient in pharmaceutical VO
2+And VO
2 +Or
Said active ingredient in pharmaceutical is K
+, Na
+, Fe
2+, Al
3+, Ti
4+, Se
4+, Li
+And/or Ge
4+, VO
2+And VO
2 +Wherein, described K
+, Na
+, Fe
2+, Al
3+, Ti
4+, Se
4+, Li
+, Ge
4+Content preferably be respectively V integral molar quantity 10
-6～10
-5Doubly.Described VO
2 +Content is preferably VO
2+0.5%～5% of mole.
Said medicine can adopt conventional method that above-mentioned each activity is made according to mixed in molar ratio, according to concrete needs, also can add acceptable accessories.
Aforementioned pharmaceutical compositions can be the pharmaceutical dosage form of routine, and wherein, the dosage form of aforementioned pharmaceutical compositions is preferably transdermal formulation.Further, described transdermal formulation is preferably patch, varnish, liniment, aerosol, unguentum, solution or lotion.
When the dosage form of said medicine is lotion, when using, the patient can medicine of the present invention be added suitable quantity of water, and make the pH value of solution reach the acceptable faintly acid scope of human body; Soak then and use; General soak time 10～40min gets final product, and during immersion, soaks every day 1～6 time.
Second technical problem to be solved by this invention provides the following purposes of above-mentioned pharmaceutical composition:
1) is used for the purposes of the medicine of liver heat removing and eyesight improving in preparation; Or
2) purposes in preparation treatment syphilis, psoriasis, alopecia or vasculitic medicine.
Medicine of the present invention can effectively be treated syphilis, psoriasis, alopecia or vasculitis, and has the effect of liver heat removing and eyesight improving, uses medicine of the present invention not see that obvious toxic and side effects is arranged, and drug effect is fast.The present invention is that syphilis, psoriasis, alopecia or vasculitic treatment provide a kind of new selection, has vast market prospect.
The specific embodiment
Pharmaceutical composition of the present invention comprises the inorganic acid salt of following active component: tetravalence V.
Further, better for the drug effect that makes medicine, the active component of aforementioned pharmaceutical compositions also comprises the inorganic acid salt of pentavalent V.Wherein, the content of vanadium of the inorganic acid salt of pentavalent V be preferably tetravalence V the inorganic acid salt content of vanadium 0.5%～5%.
Further, better for the drug effect that makes medicine, the active component of aforementioned pharmaceutical compositions also comprises proper inorganic acid, and wherein, said mineral acid can be hydrochloric acid, sulphuric acid or phosphoric acid.When active ingredient in pharmaceutical contained mineral acid, it was preferably solution dosage, and the consumption of mineral acid gets final product to guarantee that active component dissolves fully.
Further, better for the drug effect that makes medicine, the active component of aforementioned pharmaceutical compositions also comprises the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge.Wherein, the inorganic acid salt content of K, Na, Fe, Al, Ti, Se, Li, Ge preferably be respectively V the inorganic acid salt integral molar quantity 10
-6～10
-5Doubly; The inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is preferably chlorate, sulfate or phosphate.
The active component of aforementioned pharmaceutical compositions can be merely the inorganic acid salt of tetravalence V.
Wherein, the active component of aforementioned pharmaceutical compositions can also be inorganic acid salt and the proper inorganic acid of tetravalence V; Described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid.When active ingredient in pharmaceutical contained mineral acid, it was preferably solution dosage, and the consumption of mineral acid gets final product to guarantee that active component dissolves fully.
Wherein, the active component of aforementioned pharmaceutical compositions can also be the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge and the inorganic acid salt of tetravalence V; The inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate.The inorganic acid salt content of described K, Na, Fe, Al, Ti, Se, Li, Ge preferably be respectively tetravalence V the inorganic acid salt mole 10
-6～10
-5Doubly.
Wherein, the active component of aforementioned pharmaceutical compositions can also be the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge, the inorganic acid salt of tetravalence V and proper inorganic acid; Described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid; The inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate.The inorganic acid salt content of described K, Na, Fe, Al, Ti, Se, Li, Ge preferably be respectively tetravalence V the inorganic acid salt mole 10
-6～10
-5Doubly.
Wherein, the active component of aforementioned pharmaceutical compositions also can be the inorganic acid salt of tetravalence V and the inorganic acid salt of pentavalent V.The content of vanadium of the inorganic acid salt of described pentavalent V be preferably tetravalence V the inorganic acid salt content of vanadium 0.5%～5%.
Wherein, said active ingredient in pharmaceutical can also be the inorganic acid salt of tetravalence V, inorganic acid salt and the proper inorganic acid of pentavalent V; Described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid.The content of vanadium of the inorganic acid salt of described pentavalent V be preferably tetravalence V the inorganic acid salt content of vanadium 0.5%～5%.
Wherein, said active ingredient in pharmaceutical can also be the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge, the inorganic acid salt of the inorganic acid salt of tetravalence V and pentavalent V; The inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate.The content of vanadium of the inorganic acid salt of described pentavalent V be preferably tetravalence V the inorganic acid salt content of vanadium 0.5%～5%.Further, the inorganic acid salt content of described K, Na, Fe, Al, Ti, Se, Li, Ge preferably be respectively V the inorganic acid salt integral molar quantity 10
-6～10
-5Doubly.
Wherein, said active ingredient in pharmaceutical can also be the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge, the inorganic acid salt of tetravalence V, the inorganic acid salt of pentavalent V and proper inorganic acid; Described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid; The inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate.The content of vanadium of the inorganic acid salt of described pentavalent V be preferably tetravalence V the inorganic acid salt content of vanadium 0.5%～5%.Further, the inorganic acid salt content of described K, Na, Fe, Al, Ti, Se, Li, Ge preferably be respectively V the inorganic acid salt integral molar quantity 10
-6～10
-5Doubly.
Wherein, the inorganic acid salt of the V in the aforementioned pharmaceutical compositions is preferably sulfate, chlorate or phosphate.Further, when V was tetravalence, the inorganic acid salt of V was preferably: VCl
4, VOCl
2, VOSO
4, (VO)
3(PO
4)
2, VOHPO
4Or VO (H
2PO
4)
2When V was pentavalent, the inorganic acid salt of V was preferably VOCl
3, (VO
2)
2(SO
4)
3, VOPO
4, (VO)
2(HPO
4)
3Or VO (H
2PO
4)
3
Inventor of the present invention is through discovering that the vanadium cation that contains in the pharmaceutical composition of the present invention is a main active.Therefore, the present invention also provides a kind of pharmaceutical composition, and it comprises following active component: VO
2+
Further, the active component of aforementioned pharmaceutical compositions also comprises VO
2 +Wherein, VO
2 +Content is preferably VO
2+0.5%～5% of mole.
Further, the active component of aforementioned pharmaceutical compositions also comprises K
+, Na
+, Fe
2+, Al
3+, Ti
4+, Se
4+, Li
+And/or Ge
4+Wherein, K
+, Na
+, Fe
2+, Al
3+, Ti
4+, Se
4+, Li
+, Ge
4+Content preferably be respectively V integral molar quantity 10
-6～10
-5Doubly.
Further, active ingredient in pharmaceutical of the present invention also can be VO
2+Or
Said active ingredient in pharmaceutical VO
2+And VO
2 +Or
Said active ingredient in pharmaceutical is K
+, Na
+, Fe
2+, Al
3+, Ti
4+, Se
4+, Li
+And/or Ge
4+, VO
2+And VO
2 +Wherein, described K
+, Na
+, Fe
2+, Al
3+, Ti
4+, Se
4+, Li
+, Ge
4+Content preferably be respectively V integral molar quantity 10
-6～10
-5Doubly.Described VO
2 +Content is preferably VO
2+0.5%～5% of mole.
Said medicine can adopt conventional method that above-mentioned each activity is made according to mixed in molar ratio, according to concrete needs, also can add acceptable accessories.
Aforementioned pharmaceutical compositions can be the pharmaceutical dosage form of routine, and wherein, the dosage form of aforementioned pharmaceutical compositions is preferably transdermal formulation.Further, described transdermal formulation is preferably patch, varnish, liniment, aerosol, unguentum, solution or lotion.
When the dosage form of said medicine is lotion, when using, the patient can medicine of the present invention be added suitable quantity of water, and make the pH value of solution reach the acceptable faintly acid scope of human body; Soak then and use; General soak time 10～40min gets final product, and during immersion, soaks every day 1～6 time.
The present invention also provides the following purposes of aforementioned pharmaceutical compositions:
1) is used for the purposes of the medicine of liver heat removing and eyesight improving in preparation; Or
2) purposes in preparation treatment syphilis, psoriasis, alopecia or vasculitic medicine.
Do further description below in conjunction with the embodiment specific embodiments of the invention, therefore do not limit the present invention among the described scope of embodiments.
The preparation of embodiment 1 medicine
Medicine according to mol ratio preparation table 1.
The set of dispense of table 1 medicine is than (mol/L)
The drug prepared dosage form is a lotion, adds water during use and is mixed with pH value and is about and soaks behind 5.5 the solution or sassafras is washed use, and soak time is 10～40min.
The test of Test Example 1 Transdermal absorption
Experimental technique and step: the Transdermal absorption appearance TT-8 that adopts the just logical Science and Technology Ltd. in Tianjin to produce carries out percutaneous and absorbs diffusion experiment.Adopt Chengdu to reach the qualified adult wistar rat of large biological company limited quarantine, body weight 200～220g is as laboratory animal.With the cropping of rat elder generation, use 5wt%Na then
2The processing of losing hair or feathers of S solution, the depilation back was put to death rat on the 2nd day, and bark fetching is removed subcutaneus adipose tissue, carries out transdermal experiment.Press from both sides rat skin between diffusion cell lid and the diffusion cell during experiment, the diffusion cell lid adds test solution, and diffusion cell adds the PBS buffer of pH7.4, and buffer adopts ultra-pure water (containing vanadium less than 0.01ug/ml) preparation.After experiment finishes; Get buffer in the diffusion cell with 50ml volumetric flask standardize solution (volumetric flask in advance through ultra-pure water clean repeatedly); Detect content of vanadium in the PBS buffer (promptly absorb contain vanadium ion concentration) with ICP; Or other ion concentration (ion concentration that promptly absorbs), if the content of vanadium in the buffer or other ion concentration have raising, prove that then this ion can pass through Transdermal absorption.According to assay, the result is carried out the secondary experiment with the big test group of expection difference, if result of the test is then averaged as a result of with result of the test is approaching for the first time for the second time; If for the second time result of the test differs greatly with result of the test for the first time, then test for the third time, get two groups of the most close data result meansigma methodss as experimental result according to three experimental results.
Sulfate preparation with vanadium contains VO
2+, VO
2 +, Fe
2+, Al
3+, K
+, Na
+, Se, Li
+Isoionic solution is measured its percutaneous assimilation effect respectively with step according to the method described above.Specific as follows:
1, VO
2+The percutaneous absorption data:
Cation in the testing liquid is VO
2+, anion is SO
4 2-PBS buffer V＜0.01ug/ml, K
+=134.9ug/ml, Na
+=1336ug/ml.
Transdermal absorption time 30min, stock solution (being the testing liquid of not diluted) pH value is 0.5, the VO in the stock solution
2+Concentration is counted 100g/L with vanadium, 40 ℃ of temperature, and the Transdermal absorption data of testing liquid are as shown in table 2, wherein, the VO of absorption
2+Concentration is the concentration in vanadium.
(the VO of table 2 testing liquid
2+) Transdermal absorption result
2, VO
2+, Fe
2+, Al
3+, K
+, Na
+, Se
4+, Li
+The percutaneous absorption data:
Cation in the testing liquid is VO
2+, Fe
2+, Al
3+, K
+, Na
+, Se
4+, Li
+, anion is SO
4 2-PBS buffer V＜0.01ug/ml, Fe
2+＜0.01ug/ml, Al
3+＜0.01ug/ml, Li
+＜0.01ug/ml, Se
4+＜0.01ug/ml, K
+=134.9ug/ml, Na
+=1336ug/ml.
Transdermal absorption time 30min, stock solution (being the testing liquid of not diluted) pH value is 0.5, the VO in the stock solution
2+Concentration is counted 100g/L with vanadium, Fe
2+, Al
3+, K
+, Na
+, Se
4+, Li
+Concentration be respectively 1.5*10
-5Mol/L, 10
-5Mol/L, 1.5*10
-5Mol/L, 1.5*10
-5Mol/L, 10
-5Mol/L, 10
-6Mol/L, 40 ℃ of temperature, the Transdermal absorption data of testing liquid are as shown in table 3, wherein, the VO of absorption
2+Concentration is the concentration in vanadium, and the ion concentration that absorbs described in the table is the ion concentration that increases in the buffer, down together.
(the VO of table 3 testing liquid
2+, Fe
2+, Al
3+, K
+, Na
+, Se
4+, Li
+) Transdermal absorption result
3, VO
2+, VO
2 +(mol ratio 100: 5) percutaneous absorption data
Cation in the testing liquid is VO
2+, VO
2 +, anion is SO
4 2-PBS buffer V＜0.01ug/ml, K
+=134.9ug/ml, Na
+=1336ug/ml.
Transdermal absorption time 30min, stock solution (being the testing liquid of not diluted) pH value is 1.5, the VO in the stock solution
2+, VO
2 +Total concentration is counted 100g/L with vanadium, 40 ℃ of temperature, and the Transdermal absorption data of testing liquid are as shown in table 4, wherein, the VO of absorption
2+, VO
2 +Concentration is the total concentration in vanadium.
(the VO of table 4 testing liquid
2+, VO
2 +) Transdermal absorption result
Can find out that from table 2～4 the Transdermal absorption effect of medicine of the present invention is better.
Test Example 2 adopts Drug therapy alopecia of the present invention
Open * *, man, 48 years old.Began to occur the deliquescing of hair hair quality in 2007, New Development is soft, the fracture symptom.Beginning in 2008 is big owing to operating pressure, the further variation of hair quality, and hair begins to come off, alopecia in 2009 1 year; Head 2 places occur and takes off light basically like the copper coin hair greatly, and the dizzy heart is tired, blurring of vision; Because job demand, conscious alopecia influence image, unusual irritated.Bring into use medicine of the present invention (embodiment 1, numbering 1) hair washing in January, 2010, a week 2 times; Use after 2 months continuously, take off the light director and go out fine hair, the alopecia phenomenon reduces; To in April, 2010, patient's alopecia phenomenon disappears basically, and hair takes off the light place and grows normal hair again.
The liver heat removing and eyesight improving effect of Test Example 3 medicines of the present invention
Open * *, man, 56 years old.Patient diagnosis in 2007 is " a hepatitis B small three positive ", and weak, sleepy, blurred vision symptom appears in the patient at the beginning of 2010, and eyes are interfered symptom.In February, 2010, the patient used medicine of the present invention (embodiment 1, numbering 6) foot bath, each 30min, every day 1 time.Patient's spirit improves after 1 month, and is happy, the hobby motion, and eye is done, the blurred vision symptom takes a turn for the better.Use continuously after 4 months, the patient is sleepy, and weak phenomenon disappears.Hospital's health check-up finds that liver function indexs such as transaminase, bilirubin, bile acid significantly take a turn for the better.The patient is in after treatment at present.
Test Example 4 adopts Drug therapy vasculitis of the present invention
Tang * *, man, 50 years old.In July, 2009 patient's right crus of diaphragm occur red and swollen, pain unbearably, hospital diagnosis is a thromboangiitis obliterans, the right lower extremity second phase, give the treatment of Chinese medicine activating blood circulation to dissipate blood stasis, but therapeutic effect is undesirable.In January, 2010, the patient used medicine of the present invention (embodiment 1, numbering 2) foot bath, 1 time every night, each 30min.Use continuously after 3 months, patient's right crus of diaphragm is red and swollen to disappear, and examination in hospital lower limb disturbance of blood circulation disappears, and vasculitis is cured.
Test Example 5 adopts Drug therapy syphilis of the present invention
Sieve * *, man, 30 years old.Hospital's health check-up syphilis antibody was positive in 2009.Taked regular antisyphilitic treatment 1 year in regular hospital, the experiment of non-syphilitic leptospira antigen can not be turned out cloudy all the time.Use medicine of the present invention (embodiment 1, numbering 4) foot bath in July, 2009,1 time every night, each 30min, after four months, examination in hospital syphilis antibody serum titer descends.Continue to strengthen treatment four months, examination in hospital syphilis is cured.
Test Example 6 adopts Drug therapy psoriasis of the present invention
The king * *, woman, 33 years old.In January, 2009, silver bits piece appearred in patient's offside ancon and right knee joint, was " psoriasis " at hospital diagnosis, through treatments such as hospital take traditional Chinese medicine, baths, and DeGrain, and the trend that progressively enlarges is arranged.In February, 2010, the patient uses medicine of the present invention (embodiment 1, numbering 6) foot bath, 1 time every night, each 30min, and with medicine scouring diseased region of the present invention, every day 1 time, use 3 months continuously after, ancon and right knee joint skin lesion position take a turn for the better fully.
Claims (24)
1. pharmaceutical composition, it is characterized in that: described pharmaceutical composition comprises the inorganic acid salt of following active component: tetravalence V.
2. pharmaceutical composition according to claim 1 is characterized in that: said active ingredient in pharmaceutical also comprises the inorganic acid salt of pentavalent V.
3. pharmaceutical composition according to claim 2 is characterized in that: the content of vanadium of the inorganic acid salt of pentavalent V be tetravalence V the inorganic acid salt content of vanadium 0.5%～5%.
4. according to each described pharmaceutical composition of claim 1～3, it is characterized in that: said active ingredient in pharmaceutical also comprises proper inorganic acid, and wherein, said mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid.
5. according to each described pharmaceutical composition of claim 1～4, it is characterized in that: said active ingredient in pharmaceutical also comprises the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge.
6. pharmaceutical composition according to claim 5 is characterized in that: the inorganic acid salt content of K, Na, Fe, Al, Ti, Se, Li, Ge be respectively V the inorganic acid salt integral molar quantity 10
-6～10
-5Doubly; The inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate.
7. pharmaceutical composition according to claim 1 is characterized in that: said active ingredient in pharmaceutical is the inorganic acid salt of tetravalence V; Or
Said active ingredient in pharmaceutical is inorganic acid salt and the proper inorganic acid of tetravalence V; Described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid; Or
Said active ingredient in pharmaceutical is the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge and the inorganic acid salt of tetravalence V; The inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate; Or
Said active ingredient in pharmaceutical is the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge, the inorganic acid salt of tetravalence V and proper inorganic acid; Described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid; The inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate.
8. pharmaceutical composition according to claim 7 is characterized in that: the inorganic acid salt content of described K, Na, Fe, Al, Ti, Se, Li, Ge be respectively tetravalence V the inorganic acid salt mole 10
-6～10
-5Doubly.
9. pharmaceutical composition according to claim 1 is characterized in that: said active ingredient in pharmaceutical is the inorganic acid salt of tetravalence V and the inorganic acid salt of pentavalent V; Or
Said active ingredient in pharmaceutical is the inorganic acid salt of tetravalence V, inorganic acid salt and the proper inorganic acid of pentavalent V; Described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid; Or
Said active ingredient in pharmaceutical is the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge, the inorganic acid salt of the inorganic acid salt of tetravalence V and pentavalent V; The inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate; Or
Said active ingredient in pharmaceutical is the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge, the inorganic acid salt of tetravalence V, the inorganic acid salt of pentavalent V and proper inorganic acid; Described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid; The inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate.
10. pharmaceutical composition according to claim 9 is characterized in that: the inorganic acid salt content of described K, Na, Fe, Al, Ti, Se, Li, Ge be respectively V the inorganic acid salt integral molar quantity 10
-6～10
-5Doubly.
11., it is characterized in that according to claim 9 or 10 described pharmaceutical compositions: the content of vanadium of the inorganic acid salt of pentavalent V be tetravalence V the inorganic acid salt content of vanadium 0.5%～5%.
12. according to each described pharmaceutical composition of claim 1～11, it is characterized in that: the inorganic acid salt of described tetravalence V is sulfate, chlorate or the phosphate of tetravalence V; The inorganic acid salt of described pentavalent V is sulfate, chlorate or the phosphate of pentavalent V.
13. pharmaceutical composition according to claim 12 is characterized in that: when V was tetravalence, the inorganic acid salt of V was: VCl
4, VOCl
2, VOSO
4, (VO)
3(PO
4)
2, VOHPO
4Or VO (H
2PO
4)
2When V was pentavalent, the inorganic acid salt of V was VOCl
3, (VO
2)
2(SO
4)
3, VOPO
4, (VO)
2(HPO
4)
3Or VO (H
2PO
4)
3
14. a pharmaceutical composition is characterized in that described pharmaceutical composition comprises following active component: VO
2+
15. pharmaceutical composition according to claim 14 is characterized in that: said active ingredient in pharmaceutical also comprises VO
2 +
16. pharmaceutical composition according to claim 15 is characterized in that: VO
2 +Content is VO
2+0.5%～5% of mole.
17. according to each described pharmaceutical composition of claim 14～16, it is characterized in that: said active ingredient in pharmaceutical also comprises K
+, Na
+, Fe
2+, Al
3+, Ti
4+, Se
4+, Li
+And/or Ge
4+
18. pharmaceutical composition according to claim 17 is characterized in that: K
+, Na
+, Fe
2+, Al
3+, Ti
4+, Se
4+, Li
+, Ge
4+Content be respectively V integral molar quantity 10
-6～10
-5Doubly.
19. pharmaceutical composition according to claim 14 is characterized in that: said active ingredient in pharmaceutical is VO
2+Or
Said active ingredient in pharmaceutical VO
2+And VO
2 +Or
Said active ingredient in pharmaceutical is K
+, Na
+, Fe
2+, Al
3+, Ti
4+, Se
4+, Li
+And/or Ge
4+, VO
2+And VO
2 +
20. pharmaceutical composition according to claim 19 is characterized in that: described K
+, Na
+, Fe
2+, Al
3+, Ti
4+, Se
4+, Li
+, Ge
4+Content be respectively V integral molar quantity 10
-6～10
-5Doubly.
21., it is characterized in that: described VO according to claim 19 or 20 described pharmaceutical compositions
2 +Content is VO
2+0.5%～5% of mole.
22. according to each described pharmaceutical composition of claim 1～21, it is characterized in that: the dosage form of said pharmaceutical composition is a transdermal formulation.
23. pharmaceutical composition according to claim 22 is characterized in that: described transdermal formulation is patch, varnish, liniment, aerosol, unguentum, solution or lotion.
24. the following purposes of each described pharmaceutical composition of claim 1～23:
1) is used for the purposes of the medicine of liver heat removing and eyesight improving in preparation; Or
2) purposes in preparation treatment syphilis, psoriasis, alopecia or vasculitic medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110125426 CN102309516A (en) | 2010-06-24 | 2011-05-16 | Drug composition and application thereof |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010208132.5 | 2010-06-24 | ||
| CN201010208132 | 2010-06-24 | ||
| CN201010216341 | 2010-07-02 | ||
| CN201010216341.4 | 2010-07-02 | ||
| CN 201110125426 CN102309516A (en) | 2010-06-24 | 2011-05-16 | Drug composition and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102309516A true CN102309516A (en) | 2012-01-11 |
Family
ID=43450946
Family Applications (20)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102980383A Active CN101947238B (en) | 2010-06-24 | 2010-09-30 | Pharmaceutical composition for treating cancer and application thereof |
| CN2010102988277A Active CN101953846B (en) | 2010-06-24 | 2010-09-30 | Application of medicinal composition to preparing medicament for treating diabetes |
| CN2010105414518A Active CN101978965B (en) | 2010-06-24 | 2010-11-12 | Use of medicine in treating diabetes |
| CN2010105415845A Active CN101961347B (en) | 2010-06-24 | 2010-11-12 | Medicinal composition for treating cancer and use thereof |
| CN 201110125280 Pending CN102309508A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating anemia |
| CN2011101254105A Pending CN102309512A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating rheumatism |
| CN2011101255659A Pending CN102309517A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating rheumatism |
| CN2011101250956A Pending CN102309505A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating organic sexual dysfunction |
| CN2011101254209A Pending CN102309515A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating insomnia |
| CN2011101253672A Pending CN102309511A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating insomnia |
| CN2011101254196A Pending CN102309514A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating hypertensive disease |
| CN2011101258093A Pending CN102309518A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating anemia |
| CN201110125431.7A Active CN102302510B (en) | 2010-06-24 | 2011-05-16 | Medicinal composition and application thereof |
| CN2011101253009A Pending CN102309510A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating osteoporosis |
| CN201110125808.9A Active CN102302511B (en) | 2010-06-24 | 2011-05-16 | Application of medicinal composition to preparation of medicine for treating organic sexual dysfunction |
| CN2011101251677A Pending CN102309506A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating osteoporosis |
| CN2011101252951A Pending CN102309509A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of analgesic drugs |
| CN 201110125426 Pending CN102309516A (en) | 2010-06-24 | 2011-05-16 | Drug composition and application thereof |
| CN2011101251785A Pending CN102309507A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of analgesic drugs |
| CN2011101254177A Pending CN102309513A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating hypertensive disease |
Family Applications Before (17)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102980383A Active CN101947238B (en) | 2010-06-24 | 2010-09-30 | Pharmaceutical composition for treating cancer and application thereof |
| CN2010102988277A Active CN101953846B (en) | 2010-06-24 | 2010-09-30 | Application of medicinal composition to preparing medicament for treating diabetes |
| CN2010105414518A Active CN101978965B (en) | 2010-06-24 | 2010-11-12 | Use of medicine in treating diabetes |
| CN2010105415845A Active CN101961347B (en) | 2010-06-24 | 2010-11-12 | Medicinal composition for treating cancer and use thereof |
| CN 201110125280 Pending CN102309508A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating anemia |
| CN2011101254105A Pending CN102309512A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating rheumatism |
| CN2011101255659A Pending CN102309517A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating rheumatism |
| CN2011101250956A Pending CN102309505A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating organic sexual dysfunction |
| CN2011101254209A Pending CN102309515A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating insomnia |
| CN2011101253672A Pending CN102309511A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating insomnia |
| CN2011101254196A Pending CN102309514A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating hypertensive disease |
| CN2011101258093A Pending CN102309518A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating anemia |
| CN201110125431.7A Active CN102302510B (en) | 2010-06-24 | 2011-05-16 | Medicinal composition and application thereof |
| CN2011101253009A Pending CN102309510A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating osteoporosis |
| CN201110125808.9A Active CN102302511B (en) | 2010-06-24 | 2011-05-16 | Application of medicinal composition to preparation of medicine for treating organic sexual dysfunction |
| CN2011101251677A Pending CN102309506A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating osteoporosis |
| CN2011101252951A Pending CN102309509A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of analgesic drugs |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011101251785A Pending CN102309507A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of analgesic drugs |
| CN2011101254177A Pending CN102309513A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating hypertensive disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (20) | CN101947238B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104398788A (en) * | 2014-11-25 | 2015-03-11 | 孙莉莉 | Traditional Chinese medicine electuary for treating insomnia and preparation method for traditional Chinese medicine electuary |
| CN106692546A (en) * | 2015-11-14 | 2017-05-24 | 张立 | Medicinal liquor for treating rheumatism and ostealgia |
| CN107375254A (en) * | 2017-08-30 | 2017-11-24 | 李炜 | A kind of external plaster and its application method for being used to treat diabetes |
| CN107485706A (en) * | 2017-09-01 | 2017-12-19 | 仲崇允 | A kind of Chinese medicine for treating breast cancer |
| CN114177196A (en) * | 2020-09-14 | 2022-03-15 | 湖南方升泰医药科技有限公司 | Vanadium compounds for use in methods of treating pain |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1140997A (en) * | 1994-01-18 | 1997-01-22 | 西奈山医院公司 | Vanadate compounds for the treatment of proliferative disorders metastases and drug resistant tumors |
| WO2005074910A1 (en) * | 2004-02-06 | 2005-08-18 | Helsingfors Institution För Bioimmunterapi Ab | Composition, comprising l-serine, l-isoleucine, folic acid and trace elements, for treating psoriasis |
| US20070066682A1 (en) * | 2005-07-01 | 2007-03-22 | Exposito Miriam R | Arylalkylamine vanadium (V) salts for the treatment and/or prevention of Diabetes mellitus |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL121748A0 (en) * | 1997-09-11 | 1998-02-22 | Yeda Res & Dev | Vanadium complexes of hydroxamates and pharmaceutical compositions comprising them |
| CN1118243C (en) * | 1999-12-17 | 2003-08-20 | 王将克 | Nutritive soybean-pumpkin powder |
| US6689385B2 (en) * | 2000-11-03 | 2004-02-10 | Chronorx Llc | Formulations for the treatment of insulin resistance and type 2 diabetes mellitus |
| CN1178946C (en) * | 2000-11-28 | 2004-12-08 | 昆明贵金属研究所 | Vanadium compound and its preparing process and usage |
| US6693094B2 (en) * | 2001-03-22 | 2004-02-17 | Chrono Rx Llc | Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus |
| CN1179659C (en) * | 2002-05-20 | 2004-12-15 | 郑军武 | Prep. of vanadium-enriched nutrient extender |
| CN1413727A (en) * | 2002-09-09 | 2003-04-30 | 凌一峰 | Composite medicine for radical curing AIDS |
| CN1187091C (en) * | 2002-09-24 | 2005-02-02 | 浙江大学 | Oral vanadium replenishing agent with bimetallic oxide as carrier and its prepn and usage |
| CN1460472A (en) * | 2003-06-06 | 2003-12-10 | 乐益 | Biquanide vanadium complex plaster preparation for curing diabetes and its application |
| WO2007043606A1 (en) * | 2005-10-12 | 2007-04-19 | Genolac Bl Corporation | Antidiabetic agent comprising anionic polyamino acid-metal complex |
| CA2643299A1 (en) * | 2006-02-21 | 2007-08-30 | Astrum Therapeutics Pty. Ltd. | Compositions to reduce blood glucose levels and treat diabetes |
| CN1846711A (en) * | 2006-04-25 | 2006-10-18 | 苟仕金 | Balanced solution with trace elements for extracorporeal culture of bezoar and its prepn process |
| CN101033239A (en) * | 2007-01-31 | 2007-09-12 | 辽宁师范大学 | Preparation and structure of novel para-insulin pharmaceutical model compound |
| CN101362684A (en) * | 2008-07-23 | 2009-02-11 | 郑德龙 | Solution containing vanadium oxalate and preparation method thereof |
-
2010
- 2010-09-30 CN CN2010102980383A patent/CN101947238B/en active Active
- 2010-09-30 CN CN2010102988277A patent/CN101953846B/en active Active
- 2010-11-12 CN CN2010105414518A patent/CN101978965B/en active Active
- 2010-11-12 CN CN2010105415845A patent/CN101961347B/en active Active
-
2011
- 2011-05-16 CN CN 201110125280 patent/CN102309508A/en active Pending
- 2011-05-16 CN CN2011101254105A patent/CN102309512A/en active Pending
- 2011-05-16 CN CN2011101255659A patent/CN102309517A/en active Pending
- 2011-05-16 CN CN2011101250956A patent/CN102309505A/en active Pending
- 2011-05-16 CN CN2011101254209A patent/CN102309515A/en active Pending
- 2011-05-16 CN CN2011101253672A patent/CN102309511A/en active Pending
- 2011-05-16 CN CN2011101254196A patent/CN102309514A/en active Pending
- 2011-05-16 CN CN2011101258093A patent/CN102309518A/en active Pending
- 2011-05-16 CN CN201110125431.7A patent/CN102302510B/en active Active
- 2011-05-16 CN CN2011101253009A patent/CN102309510A/en active Pending
- 2011-05-16 CN CN201110125808.9A patent/CN102302511B/en active Active
- 2011-05-16 CN CN2011101251677A patent/CN102309506A/en active Pending
- 2011-05-16 CN CN2011101252951A patent/CN102309509A/en active Pending
- 2011-05-16 CN CN 201110125426 patent/CN102309516A/en active Pending
- 2011-05-16 CN CN2011101251785A patent/CN102309507A/en active Pending
- 2011-05-16 CN CN2011101254177A patent/CN102309513A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1140997A (en) * | 1994-01-18 | 1997-01-22 | 西奈山医院公司 | Vanadate compounds for the treatment of proliferative disorders metastases and drug resistant tumors |
| WO2005074910A1 (en) * | 2004-02-06 | 2005-08-18 | Helsingfors Institution För Bioimmunterapi Ab | Composition, comprising l-serine, l-isoleucine, folic acid and trace elements, for treating psoriasis |
| US20070066682A1 (en) * | 2005-07-01 | 2007-03-22 | Exposito Miriam R | Arylalkylamine vanadium (V) salts for the treatment and/or prevention of Diabetes mellitus |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102309512A (en) | 2012-01-11 |
| CN102309509A (en) | 2012-01-11 |
| CN102302510A (en) | 2012-01-04 |
| CN101947238A (en) | 2011-01-19 |
| CN102302511B (en) | 2015-06-03 |
| CN102302510B (en) | 2014-04-23 |
| CN101978965A (en) | 2011-02-23 |
| CN101947238B (en) | 2011-12-21 |
| CN101953846A (en) | 2011-01-26 |
| CN101978965B (en) | 2011-12-28 |
| CN101953846B (en) | 2011-12-28 |
| CN102302511A (en) | 2012-01-04 |
| CN102309511A (en) | 2012-01-11 |
| CN102309517A (en) | 2012-01-11 |
| CN102309513A (en) | 2012-01-11 |
| CN101961347A (en) | 2011-02-02 |
| CN102309507A (en) | 2012-01-11 |
| CN102309515A (en) | 2012-01-11 |
| CN102309518A (en) | 2012-01-11 |
| CN102309508A (en) | 2012-01-11 |
| CN102309505A (en) | 2012-01-11 |
| CN102309510A (en) | 2012-01-11 |
| CN102309506A (en) | 2012-01-11 |
| CN101961347B (en) | 2011-12-21 |
| CN102309514A (en) | 2012-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102614102B (en) | Dandruff-removing medicinal composition and preparation method thereof | |
| CN102309516A (en) | Drug composition and application thereof | |
| WO2023109747A1 (en) | Use of 2,4-dihydroxybenzoic acid in drug for treating iron overload diseases | |
| US20060275505A1 (en) | Method and composition for increasing the alkalinity of the body | |
| CN101053549A (en) | Spot-removing cream | |
| CN102100735B (en) | Medicinal composition for treating skin diseases | |
| CN106620041A (en) | Ancient traditional Chinese medicine blood pressure, blood sugar and cardiovascular disease regulation prescription and rehabilitation method | |
| CN108498535A (en) | A kind of povidone iodine pharmaceutical composition and its preparation method and application for treating skin and mucosa infection | |
| CN107596355A (en) | A kind of Medical pain easing, the exterior-applied gel subsided a swelling, brought down a fever and preparation method thereof | |
| CN100525751C (en) | Meridian point therapeutic plaster of high polymer multi hole energy gathering ion and its preparation method and application | |
| CN105250838B (en) | Cosmetic for treating callus | |
| CN100352461C (en) | External-use medicine for treating leucoderma and its preparing method | |
| CN102614115B (en) | Sodium dichlorophenolate self-emulsifying ointment | |
| CN1483469A (en) | Baidianxiao treaditional Chinese medicine for treating vitiligo and preparation method thereof | |
| CN110522805B (en) | Traditional Chinese medicine composition for treating alopecia and preparation method and application thereof | |
| CN107126484A (en) | It is a kind of to treat callicarpa nudiflora gel of gynaecological imflammation and preparation method thereof | |
| RU2384341C1 (en) | Pharmaceutical composition for psoriasis treatment | |
| CN114949119A (en) | Formula of antibacterial foot bath liquid for relieving fatigue, promoting blood circulation to remove blood stasis, and strengthening yang to supplement and correct health | |
| CN101380345B (en) | Multifunctional medicinal wine for mainly treating rheumatism disease and production method thereof | |
| CN1327847C (en) | Externally applied medicine for treating vitiligo and its preparation process | |
| CN109395088A (en) | A kind of ligand being used in combination with protein-based medicinal active ingredient and oral protein class pharmaceutical preparation | |
| CN102000297B (en) | Traditional Chinese medical composition for treating coronary heart disease | |
| CN101972273B (en) | Application of medicine in preparing medicines for treating diabetes mellitus | |
| CN109745431A (en) | For treating the herb mixture and its preparation method and application of psoriasis and onychomycosis | |
| CN115581662A (en) | Ointment for treating verruca plantaris |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20120111 |